after joining the study, a written consent form is signed to confirm understanding of the trial procedures.

personal health information and eligibility are verified before any study activities begin.

a series of tests are performed to record the current health status, including blood tests, imaging scans, and questionnaires about quality of life.

the results create a reference point for later comparisons during the trial.

participants are randomly placed into one of two groups: the rinatabart sesutecan plus standard of care group, or the standard of care alone group that may receive bevacizumab as the comparator.

the assignment is open‑label, meaning the participant knows which treatment is being received.

the first dose of the assigned medication is given by intravenous infusion in a clinical setting.

for rinatabart sesutecan, the dose is expressed as milligram per square meter (mg/m2) and is prepared as a solution for infusion.

for bevacizumab, the dose is expressed as milligram per kilogram (mg/kg) and is also administered intravenously.

the exact amount is calculated by the study team based on body measurements and the protocol specifications.

subsequent infusions are scheduled at regular intervals defined by the study protocol.

each visit includes the administration of the same medication, monitoring of vital signs, and assessment for any immediate reactions.

the infusion duration and any pre‑medication are managed by the clinical staff.

imaging scans are performed at predefined times to measure tumor size and determine progression‑free survival according to standard criteria.

the scans are reviewed by an independent central reviewer who is unaware of the treatment assignment.

participants complete the eortc qlq‑c30 questionnaire at scheduled intervals to assess overall health status and any changes over time.

at each visit, health professionals ask about treatment‑emergent adverse events and record any symptoms.

laboratory tests may be repeated to detect changes that could indicate toxicity.

treatment continues until disease progression, unacceptable side effects, or the end of the study period as defined by the protocol.

if discontinuation occurs, a final assessment is performed to document the reason and collect remaining outcome data.

a concluding visit includes a last set of scans, blood tests, and quality‑of‑life questionnaires.

the collected information contributes to the overall analysis of the study objectives.